At a glance
ClinicalIndex Comparison RecordN/ACompleted· 188 enrolled
Drug / intervention
Pegloticasebiological
Likely dose
Pegloticase 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study of the Use of KRYSTEXXA® (Pegloticase) in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy
In Brief
An observational study evaluating Pegloticase for Refractory Chronic Gout. Completed, enrolled 188 participants across 67 sites.
Detailed Summary
The primary purpose of this study is to observe patients being treated with pegloticase in a standard healthcare setting in order to evaluate the frequency and severity of infusion reactions, anaphylaxis and immune complex related events. Additionally, serious adverse events associated with pegloticase therapy will be identified.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Gout
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartNov 2011
Primary CompletionJun 2017
TodayJul 2026
First PostedNov 7, 2011
Enrollment StartNov 15, 2011
Primary CompletionJun 30, 2017
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 14.7 years ago
Interventions
Pegloticasebiological
Pegloticase 8 mg intravenous every 2 weeks